Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation

Chronic myelogenous leukaemia (CML) is a clonal malignancy of the pluripotent haematopoietic stem cell, characterised by an uncontrolled proliferation and expansion of myeloid progenitors expressing a fusion oncogene, BCR-ABL, the molecular counterpart of the Ph1 chromosome. The tyrosine kinase (TK)...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Deutsch, E, Maggiorella, L, Wen, B, Bonnet, M L, Khanfir, K, Frascogna, V, Turhan, A G, Bourhis, J
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group 2004
Assuntos:
Experimental Therapeutics
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2409959/
https://ncbi.nlm.nih.gov/pubmed/15494718
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6602190
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares